Publicity

Biotech Investors Should Consider The Four Horsemen

Biotech Investors Should Consider The Four Horsemen

One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John McCamant and frequent MoneyShow.com contributor. Medical Technology Stock Letter has had many such winners over the years, including Genentech and Pharmacyclics. We provided multiple entry points to invest in Pharmacyclics starting at $17 and in three-plus years the company was sold to AbbVie for $262 per share or $21 billion. Over the last year and a quarter, our subscribers have been enjoying incredible gains with the Four Horsemen: Esperion Therapeutics. Madrigal Pharmaceuticals, Nektar Therapeutics, Sangamo Therapeutics.

0 comments

Biotech Poised for Significant Catalysts in 2018

As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.

0 comments

MoneyShow’s Top Stock Pickers of 2017

Biotechnology expert John McCamant deserves special recognition; his top pick from last year rose an astounding 519%. We’ve asked John, and all these other outstanding advisors, to share their updated opinions on these top performing stocks from last year’s Top Picks 2017 report.

0 comments

Myovant: Drug Offers ‘Best-in-Class’ Potential

Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.

0 comments

Esperion: Grand Slam in Cholesterol Reduction

Esperion (ESPR) hit a grand slam with triple therapy data, submitting an NDA filing and enrollment ahead of schedule, asserts biotech expert John McCamant, editor of The Medical Technology Stock Letter.

0 comments

Intrexon: Biotech, Biofuels & Fish Farming

Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.

0 comments

Top Picks 2017: Madrigal

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

0 comments

Top Picks 2017: The Medicines Company

The next-generation of cholesterol drugs were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of the Medical Technology Stock Letter.

0 comments

Top Picks 2017: Incyte (1-06-2017)

This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.

0 comments

10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

0 comments

Incyte: A Promising Pipeline (11-14-2016)

John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stock Incyte (INCY), noting that the company will have a very strong presence at the American Society of Hematology (ASH) Annual Meeting 2016 in early December.

0 comments

Trump Victory Brings V-Shaped Reaction (11-9-16)

The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.

0 comments

Alkermes: Progress in Treating Depression (11-2-2016)

This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.

0 comments

Catalysts in Biotech (8-19-2016)

John McCamant of BioInvest’s Medical Technology Stock Letter, updates us on the state of the sector, the primary catalysts he sees over the rest of the year, and a trio of favorite stocks poised for potentially exciting results.

0 comments

Opinion: Four reasons for investors to buy biotechnology stocks now (05-20-2016)

Four reasons for investors to buy biotechnology stocks now: Beaten-down biotechnology stocks have been so cheap for so long, rattled investors pray every day that a big drug company with firepower will swoop in and buy one to spark interest in the industry.

0 comments

Pacira: Safer than Opioids? (05-19-2016)

The move away from opiods is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.

0 comments

Opinion: Dozens of biotech companies are ‘free’ for investors’ taking (2-16-2016)

Dozens of biotech companies are ‘free’ for investors’ taking

0 comments

Top Picks 2016: Pharmaceuticals (1-28-2016)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-The Medicines Company. #MDCO

0 comments

Top Picks 2016: Anthera (1-15-2016)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-Anthera Pharmaceuticals. #ANTH

0 comments

2015’s Top Performers (1-12-2016)

John McCamant, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his biotech stock picks for 2015, one of which (FPRX) that has risen 50%. #FPRX #PCYC

0 comments